Evaluation of High-Throughput Serological Tests for SARS-CoV-2

Serological testing plays a critical role in tracking SARS-CoV-2 infections and supporting public health responses. While PCR tests detect active viral RNA, antibody tests reveal past exposure and immune response. Multiple commercial SARS-CoV-2 antibody tests have received emergency use authorization, but their comparative performance remains unclear. Prior research has shown that antibody tests vary in sensitivity and specificity, but no prior work had resolved the consistency of high-throughput tests in clinical settings. This gap motivated a focused evaluation of four widely used assays. The study aimed to clarify whether these tests produce consistent results across different platforms. No prior work had resolved the agreement of these specific assays in a clinical laboratory setting. Understanding this consistency is essential for interpreting serological data in large-scale studies. This uncertainty drives the need for validation studies like the one described.

The goal of this study was to evaluate the agreement of four high-throughput SARS-CoV-2 IgG antibody tests. These tests are used in clinical labs to detect past infections. The researchers wanted to determine if these assays produce similar results when applied to the same samples. The motivation stems from the need for reliable serological data to support epidemiological studies and vaccine development. No prior work had resolved the consistency of these specific tests in a clinical setting. The authors aimed to assess agreement and false-positive rates across different platforms. This evaluation is crucial for interpreting serological data in public health contexts. The study focused on four EUA-approved tests: Abbott Architect, DiaSorin Liaison, Euroimmun, and Ortho Vitros.

The researchers evaluated four SARS-CoV-2 IgG antibody tests approved for emergency use. They analyzed a panel of clinical samples to assess agreement between the assays. The study used a cross-sectional design with a diverse sample set. Each test was applied to the same set of specimens to compare results. The team measured agreement using statistical methods like percent agreement and kappa statistics. They also assessed false-positive rates across all tests. The study included a mix of positive and negative control samples. The results were compared to a reference method to ensure accuracy.

The study found excellent agreement among the four SARS-CoV-2 IgG antibody tests. Percent agreement ranged from 98.7% to 99.5% across the assays. Kappa statistics indicated strong concordance between the tests. False-positive rates were rare, with less than 0.5% of samples showing false reactivity. The Abbott Architect and DiaSorin Liaison showed the highest agreement. Euroimmun and Ortho Vitros also demonstrated strong consistency. No single test outperformed the others in all metrics. These findings suggest that the tested assays are reliable for clinical use.

The authors concluded that the four high-throughput SARS-CoV-2 IgG tests show excellent agreement in clinical samples. They propose that these assays can be used interchangeably in most settings. The rare false-positive reactivity suggests high specificity across all tests. The authors suggest that these findings support the use of these tests in large-scale serological studies. They emphasize the importance of consistent results for public health surveillance. The study does not claim that one test is superior to the others. The authors suggest that the tested assays are suitable for clinical and epidemiological use. These conclusions are based on the observed agreement and low false-positive rates.